公开(公告)号：EP3427734B1

公开(公告)日：2024-07-10

申请号：EP18188224.2

申请日：2012-07-18

IPC分类号： A61K31/436 ,  A61P25/28 ,  A61K31/05 ,  A61K31/192 ,  A61K31/404 ,  A61K31/42 ,  A61K31/44 ,  A61K31/506 ,  A61K31/551 ,  A61K38/19 ,  A61K38/20 ,  A61K38/21 ,  A61K38/39 ,  A61K38/48 ,  A61K39/00

CPC分类号： A61K2039/5556620130101 ,  A61K38/195 ,  A61K38/208 ,  A61K38/21 ,  A61K38/39 ,  A61K38/484 ,  A61K31/192 ,  A61K31/404 ,  A61K31/42 ,  A61K31/44 ,  A61K31/506 ,  A61K31/551 ,  A61K39/0007 ,  A61K31/05 ,  A61K31/436 ,  A61K38/1709 ,  A61K38/212 ,  A61P25/28 ,  A61P43/00

公开(公告)号：EP3412304A2

公开(公告)日：2018-12-12

申请号：EP18181508.5

申请日：2014-10-22

申请人： The United States of America, as represented by The Secretary, Department of Health and Human Services

发明人： Schlom, Jeffrey ,  Tsang, Kwong-Yok

IPC分类号： A61K38/08 ,  A61K38/10 ,  C07K7/06 ,  C07K7/08 ,  C12N15/81

CPC分类号： C07K14/4727 ,  A61K31/00 ,  A61K38/00 ,  A61K38/191 ,  A61K38/193 ,  A61K38/195 ,  A61K38/20 ,  A61K38/217 ,  A61K38/22 ,  A61K39/0011 ,  A61K39/39 ,  A61K45/06 ,  A61K2039/5154 ,  A61K2039/53 ,  A61K2039/55588 ,  C07K14/82 ,  C07K2319/00 ,  C12N7/00 ,  C12N2710/24143 ,  C12N2710/24171 ,  A61K2300/00

摘要： The invention provides a human cytotoxic T lymphocyte (CTL) agonist epitope from the C-terminal subunit of mucin 1 (MUC1-C), which can be used as a peptide, polypeptide (protein), and/or in vaccine or other composition for the prevention or therapy of cancer. The invention further provides a nucleic acid encoding the peptide, protein, or polypeptide, a vector comprising the nucleic acid, a cell comprising the peptide, polypeptide, nucleic acid, or vector, and compositions thereof.

公开(公告)号：EP3011012B1

公开(公告)日：2018-09-12

申请号：EP14813300.2

申请日：2014-06-18

申请人： New York University

发明人： TORRES, Victor, J. ,  REYES-ROBLES, Tamara ,  ALONZO, Francis, III

IPC分类号： A61K38/16 ,  A61K38/19 ,  A61K31/255 ,  A61K31/341 ,  A61K31/44 ,  A61K31/505 ,  C07K16/12 ,  C07K16/28 ,  A61P31/04

CPC分类号： C07K16/1271 ,  A61K31/255 ,  A61K31/341 ,  A61K31/44 ,  A61K31/505 ,  A61K38/164 ,  A61K38/195 ,  A61K39/085 ,  A61K39/40 ,  A61K45/06 ,  C07K16/2896 ,  C07K2317/76 ,  G01N2800/52

摘要： The present invention relates to methods for treating and preventing Staphylococcus aureus infection and/or a condition resulting from a S. aureus infection in a subject that involves administering compositions that inhibit S. aureus interaction with CXCR1/CXCR2 and DARC cellular receptors. The present invention further relates to novel compositions for carrying out these and other methods.

公开(公告)号：EP3060232B1

公开(公告)日：2018-07-04

申请号：EP14802730.3

申请日：2014-10-22

申请人： The United States of America, as represented by The Secretary, Department of Health and Human Services

发明人： SCHLOM, Jeffrey ,  TSANG, Kwong-Yok

IPC分类号： A61K38/08 ,  A61K38/10 ,  C07K7/06 ,  C07K7/08 ,  C12N15/81

CPC分类号： C07K14/4727 ,  A61K31/00 ,  A61K38/00 ,  A61K38/191 ,  A61K38/193 ,  A61K38/195 ,  A61K38/20 ,  A61K38/217 ,  A61K38/22 ,  A61K39/0011 ,  A61K39/39 ,  A61K45/06 ,  A61K2039/5154 ,  A61K2039/53 ,  A61K2039/55588 ,  C07K14/82 ,  C07K2319/00 ,  C12N7/00 ,  C12N2710/24143 ,  C12N2710/24171 ,  A61K2300/00

摘要： The invention provides a human cytotoxic T lymphocyte (CTL) agonist epitope from the C-terminal subunit of mucin 1 (MUC1-C), which can be used as a peptide, polypeptide (protein), and/or in vaccine or other composition for the prevention or therapy of cancer. The invention further provides a nucleic acid encoding the peptide, protein, or polypeptide, a vector comprising the nucleic acid, a cell comprising the peptide, polypeptide, nucleic acid, or vector, and compositions thereof.

公开(公告)号：EP3281635A1

公开(公告)日：2018-02-14

申请号：EP17185286.6

申请日：2017-08-08

申请人： SCM Lifescience Co., Ltd.

发明人： SONG, Sun Uk ,  SUNG, Jong Hyuk

IPC分类号： A61K38/17 ,  A61K38/19 ,  A61K8/64 ,  A61Q7/00 ,  A23L33/18

CPC分类号： A61K8/64 ,  A23L33/18 ,  A61K9/06 ,  A61K38/17 ,  A61K38/1709 ,  A61K38/195 ,  A61Q7/00

摘要： Provided is a composition for preventing, treating or improving hair loss and promoting hair generation and hair growth, comprising a CXCL1 protein as an active ingredient. Further, provided is a composition for preventing, treating or improving hair loss and promoting hair generation and hair growth, comprising a CXCL1 protein and minoxidil as an active ingredient. The CXCL1 protein according to the present disclosure has no side effects at the time of treating hair loss and an excellent hair generation effect even in a short time and thus can be used as pharmaceutical products and usefully used as quasi-drugs, cosmetics and health functional foods.

摘要翻译： 本发明提供用于预防，治疗或改善脱发并促进毛发生长和毛发生长的组合物，其包含CXCL1蛋白质作为活性成分。 此外，提供一种用于预防，治疗或改善脱发并促进毛发生长和毛发生长的组合物，其包含CXCL1蛋白质和米诺地尔作为活性成分。 本发明的CXCL1蛋白质在脱发时没有副作用，即使在短时间内也具有优异的毛发生成效果，因此可以作为医药品使用，作为准药品，化妆品和保健功能有用 食物。

公开(公告)号：EP3256144A1

公开(公告)日：2017-12-20

申请号：EP16749945.8

申请日：2016-02-12

申请人： The Board of Trustees of the University of Illinois

发明人： ACKERMAN, Steven, J. ,  LAFFEY, Fan, Gao ,  HITCHINSON, Ben ,  GARNIER, Boris ,  GAPONENKO, Vadim ,  TARASOVA, Nadya ,  ABDELKARIM, Hazem

IPC分类号： A61K38/04 ,  C07K14/715 ,  A61K38/00

CPC分类号： A61K38/195 ,  A61K9/008 ,  A61K38/00 ,  A61K47/10 ,  A61K47/6813 ,  A61P11/06 ,  A61P37/08 ,  C07K14/4703 ,  C07K14/521 ,  C07K14/7158

摘要： A C—C chemokine receptor 3 (CCR3) peptide analog that exhibits biased antagonism by binding to and inhibiting ligand-mediated signaling and chemotaxis while promoting the internalization and degradation of CCR3 is provided as is a method of using the peptide analog to treat, prevent, or ameliorate one or more symptoms of an eosinophil- or CCR3-mediated disease or condition.

公开(公告)号：EP2858722B1

公开(公告)日：2017-12-13

申请号：EP13799826.6

申请日：2013-06-07

申请人： Aduro Biotech, Inc. ,  The John Hopkins University

发明人： DUBENSKY, Thomas, W. ,  LEONG, Meredith, Lai Ling ,  PARDOLL, Drew, M. ,  KIM, Young, Jun

IPC分类号： A61P37/04

CPC分类号： A61K35/13 ,  A61K9/127 ,  A61K31/7084 ,  A61K38/19 ,  A61K38/193 ,  A61K38/195 ,  A61K38/208 ,  A61K39/0011 ,  A61K39/12 ,  A61K39/21 ,  A61K2039/5152 ,  A61K2039/55555 ,  A61K2039/55561 ,  C12N2740/16034

摘要： The present invention provides a combination therapy which relies on a small molecule immune stimulator—cyclic-di-nucleotide (CDN)—that activates DCs via a recently discovered cytoplasmic receptor known as STING (Stimulator of Interferon Genes) formulated with allogeneic human tumor cell lines engineered to secrete high amounts of GM-CSF. This combination therapy can provide an ideal synergy of multiple tumor associated antigens, DC recruitment and proliferation, coupled with a potent DC activation stimulus.

公开(公告)号：EP3093023A4

公开(公告)日：2017-10-11

申请号：EP15740157

申请日：2015-01-23

申请人： QUARRYMEN & CO INC

发明人： UEDA MINORU

IPC分类号： A61K35/32 ,  A61K38/18 ,  A61K38/19 ,  A61K38/30 ,  A61P35/00

CPC分类号： A61K38/30 ,  A61K35/12 ,  A61K35/32 ,  A61K38/1841 ,  A61K38/1866 ,  A61K38/195 ,  C12N5/0664 ,  C12N5/0696 ,  C12N2500/02 ,  C12N2500/90 ,  C12N2500/99 ,  C12N2501/105 ,  C12N2501/15 ,  C12N2501/165 ,  C12N2501/21 ,  C12N2501/60 ,  C12N2501/998 ,  C12N2506/1361 ,  C12N2510/04

摘要： The purpose of the present invention is to provide a novel anticancer therapeutic having a high effect against solid cancers, lacking the side effects of chemotherapeutics, and being unlikely to cause resistance. Provided is a pharmaceutical composition for cancer treatment prepared by a method having: a stem cell production step for making immortalized stem cells by introducing four types of genes into deciduous tooth dental pulp stem cells obtained from the dental pulp of mammals; and a condition medium preparation step for culturing the immortalized stem cells for a predetermined length of time in serum-free medium at 23-27°C under conditions of low oxygen concentration at an oxygen concentration of from 0.5% to less than 20%, the pharmaceutical composition containing 1.5 times or more of insulin-like growth factor (IGF-1) and vascular endothelial growth factor (VEGF) than is contained in condition medium prepared when culturing at an oxygen concentration of 20% and otherwise identical conditions.

公开(公告)号：EP2496607B1

公开(公告)日：2017-09-27

申请号：EP10827661.9

申请日：2010-11-02

申请人： The Regents of the University of California ,  The United States Government as represented by the Department of Veterans Affairs

发明人： ROME, Leonard, H. ,  KICKHOEFER, Valerie, A. ,  DUBINETT, Steven, M. ,  SHARMA, Sherven ,  KAR, Upendra, K.

IPC分类号： C07K19/00 ,  C12N15/62 ,  C12N15/19 ,  A61K38/19 ,  A61P35/00

CPC分类号： A61K38/195 ,  A61K35/12 ,  A61K38/00 ,  A61K38/45 ,  A61K47/6921 ,  A61K48/00 ,  C07H21/00 ,  C07K7/06 ,  C07K14/47 ,  C07K14/521 ,  C07K2319/00 ,  C07K2319/01 ,  C12N5/0636 ,  C12N9/1077 ,  C12N9/96 ,  C12N15/86 ,  C12Y204/0203 ,  G01N33/535

公开(公告)号：EP2324839B1

公开(公告)日：2017-08-09

申请号：EP10012752.1

申请日：2001-06-05

申请人： The Trustees of Columbia University in the City of New York

发明人： Itescu, Silviu

IPC分类号： A61K35/14 ,  A61K35/28 ,  A61K38/19 ,  A61P9/10

CPC分类号： A61K38/195 ,  A61K35/44 ,  A61K38/193 ,  A61K2039/505 ,  C07K14/52 ,  C07K16/24 ,  C07K16/2866 ,  C12N5/0692 ,  C12N2501/21

摘要： The present invention provides a method of stimulating vasculogenesis of myocardial infarct damaged tissue in a subject comprising: (a) removing stem cells from a location in the subject; (b) recovering endothelial progenitor cells in the stem cells; (c) introducing the endothelial progenitor cells from step (b) into a different location in the subject such that the precursors migrate to and stimulate revascularization of the tissue. The stem cells may be removed directly or by mobilization. The endothelial progenitor cells may be expanded before introduction into the subject. The present invention further provides a method of inducing angiogenesis in peri-infarct tissue. The present invention further provides a method of selectively increasing the trafficking of human bone marrow-derived endothelial cell precursors to the site of tissue damaged by ischemic injury which comprises: (a) administering endothelial progenitor cells to a subject; (b) administering chemokines to the subject so as to thereby attract endothelial cell precursors to the ischemic tissue. The present invention provides a method of stimulating vasculogenesis or angiogenesis of myocardial infarct damaged tissue in a subject comprising injecting allogeneic stem cells into a subject. The present invention further provides a method of improving myocardial function in a subject that has suffered a myocardial infarct comprising any of the instant methods. The present invention further provides a method of improving myocardial function in a subject that has suffered a myocardial infarct comprising injecting G-CSF or anti-CXCR4 antibody into the subject in order to mobilize endothelial progenitor cells.

摘要翻译： 本发明提供刺激受试者中心肌梗塞受损组织的血管发生的方法，其包括：（a）从受试者中的位置移除干细胞; （b）回收干细胞中的内皮祖细胞; （c）将来自步骤（b）的内皮祖细胞引入受试者的不同位置，使得前体迁移并刺激组织的血管再生。 干细胞可以直接或通过动员移除。 内皮祖细胞可在引入受试者之前扩张。 本发明还提供了在梗塞周围组织中诱导血管生成的方法。 本发明进一步提供选择性增加人骨髓来源的内皮细胞前体向由缺血性损伤损伤的组织部位的运输的方法，该方法包括：（a）将内皮祖细胞给予受试者; （b）向受试者施用趋化因子以由此将内皮细胞前体吸引至局部缺血组织。 本发明提供刺激受试者的心肌梗塞受损组织的血管发生或血管生成的方法，包括将同种异体干细胞注射入受试者。 本发明进一步提供了改善患有心肌梗塞的受试者中的心肌功能的方法，其包含任何本发明方法。 本发明进一步提供了改善遭受心肌梗塞的受试者的心肌功能的方法，包括向受试者注射G-CSF或抗CXCR4抗体以活化内皮祖细胞。